Many people talk about the ever-changing landscape of healthcare—and this is true now more than ever. In the months to come, the sustainable growth rate (SGR), several Centers for Medicare & Medicaid Services (CMS) rules, federal debt negotiations, and sequestration are likely to come together to have an impact on physicians’ ability to provide care for Medicare beneficiaries. But how, specifically, will these factors affect community oncology?
Every day, increasing numbers of patients learn that a chemo - therapy has been developed that could save their lives, but the drug they need is unavailable, because no one is manufacturing it. Expensive to man ufacture, yet priced very low, generic sterile injectable chemotherapies are some of the drugs that are the most vulnerable to production shortages.
Read Now
Stay up to date with urology news & updates by subscribing to receive the free UPM print publications or e‑Newsletters.